TIVORBEX Drug Patent Profile

✉ Email this page to a colleague

When do Tivorbex patents expire, and when can generic versions of Tivorbex launch?

Tivorbex is a drug marketed by Genus and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-seven patent family members in twenty-one countries.

The generic ingredient in TIVORBEX is indomethacin. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the indomethacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tivorbex

A generic version of TIVORBEX was approved as indomethacin by CHARTWELL MOLECULES on August 6^th, 1984.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TIVORBEX?
What are the global sales for TIVORBEX?
What is Average Wholesale Price for TIVORBEX?

Summary for TIVORBEX

International Patents:	37
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	164
Clinical Trials:	2
Patent Applications:	4,245
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TIVORBEX
What excipients (inactive ingredients) are in TIVORBEX?	TIVORBEX excipients list
DailyMed Link:	TIVORBEX at DailyMed

Drug patent expirations by year for TIVORBEX

Recent Clinical Trials for TIVORBEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sen-Jam Pharmaceutical	Phase 2
National University, Singapore	Phase 2
Iroko Pharmaceuticals, LLC	Phase 2

See all TIVORBEX clinical trials

US Patents and Regulatory Information for TIVORBEX

TIVORBEX is protected by three US patents.

Patents protecting TIVORBEX

Formulation of indomethacin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Formulation of indomethacin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PAIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-002	Feb 24, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-002	Feb 24, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TIVORBEX

See the table below for patents covering TIVORBEX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	2010239081	A novel formulation of indomethacin	⤷ Sign Up
South Korea	20150030782	A Novel formulation of indomethacin	⤷ Sign Up
South Korea	20140077945	A NOVEL FORMULATION OF INDOMETHACIN	⤷ Sign Up
Eurasian Patent Organization	201171286	НОВАЯ ТЕХНОЛОГИЯ ИЗГОТОВЛЕНИЯ ИНДОМЕТАЦИНА	⤷ Sign Up
Australia	2016200397	A Novel Formulation of Indomethacin	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for TIVORBEX

Recent Clinical Trials for TIVORBEX

Patents protecting TIVORBEX

Make Better Decisions: Try a trial or see plans & pricing